Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 71, Issue -, Pages 36-45Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2013.10.068
Keywords
Alzheimer's disease; Resveratrol derivatives; Antioxidant; beta-Amyloid aggregation; Metal chelator; Neuroprotection
Categories
Funding
- Innovative Research Team in University [IRT1193]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Project of Graduate Education Innovation of Jiangsu Province [CXZZ13_0320]
Ask authors/readers for more resources
A series of imine resveratrol derivatives (1-20) have been designed, synthesized, and evaluated as multi-targeted compounds for the treatment of Alzheimer's disease (AD). In vitro studies show that most of the molecules exhibit a significant ability to inhibit self-induced and Cu2+-induced beta-amyloid (A beta(1-42)) aggregation, and to function as potential antioxidants and biometal chelators. In particular, compound 9 is a potential lead compound for AD treatment (for compound 9, IC50 = 14.1 mu M for the antioxidant activity using DPPH free radical method; 64.6% at 20 mu M for self-induced A beta aggregation). Moreover, it is capable of decreasing reactive oxygen species (ROS) induced by Cu-A beta and shows good neuroprotective effects in human SH-SY5Y neuroblastoma cells. Taken together, these results suggest that 9 might be a promising lead compound for AD treatment. (C) 2013 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available